LEGN

AI Memo

Legend Biotech

As of 2026-09-26/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-09-26 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

Five-year CARVYKTI data require clinical and commercial interpretation • 2026-09-25

Base target: $19 / p=50% prob

Biggest risk

Legend remains heavily dependent on CARVYKTI. A small CARTITUDE-2 cohort cannot establish broad commercial impact, while cell-therapy safety, manufacturing, competitive and pipeline-execution risks remain material.

Invalidation

Break below $13 or thesis failure.

What would change my mind?

CARVYKTI's reported sales growth, positive second-quarter operating income and durable five-year clinical data could support further adoption and operating leverage. LB2501 offers longer-term optionality, but remains early-stage. [#IR-2026-08-11] Company earnings release

Research note

Recommendation

—

Confidence

medium

As of

2026-09-26

Base target

$19

p=50%

Bull target

$25

p=25%

Bear target

$13

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

CARVYKTI growth must translate into sustained operating profit
LB2501 follow-up must validate early in vivo CAR-T responses
CARVYKTI's reported sales growth, positive second-quarter operating income and durable five-year clinical data could support further adoption and operating leverage.

BearKey bullets

CARTITUDE-2 Cohort A's five-year result covers only 20 patients; broader clinical and commercial implications remain uncertain.
CARVYKTI concentration makes sales growth, access, manufacturing execution and safety disproportionately important.
LB2501 efficacy and safety observations are preliminary Phase 1 findings from a small cohort.

WatchKey bullets

Five-year CARVYKTI data require clinical and commercial interpretation

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $19 (p=50%)

Target spread vs base: +32% / -32%

Scenario probabilities

Bull Target: $25 (p=25%)Base Target: $19 (p=50%)Bear Target: $13 (p=25%)

Commentary

Company news is mildly constructive: Legend announced five-year CARVYKTI follow-up and appointed Ingrid Zhang CEO effective September 15. [#IR-2026-09-25] Company data release [#IR-2026-09-15] Company appointment release The packet does not establish a post-data share-price reaction or verified analyst revisions. Buyout speculation is not company-confirmed. Social, options, short-interest and employee measures are unavailable; their zero placeholders are not neutral observations.

As of 2026-09-26 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

CARVYKTI growth must translate into sustained operating profit
LB2501 follow-up must validate early in vivo CAR-T responses

Scenarios

Bull Target (Scenario probability)

$25 / p=25% prob

Base Target (Scenario probability)

$19 / p=50% prob

Bear Target (Scenario probability)

$13 / p=25% prob

Analysis 2026-09-26 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.20

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-09-25
Five-year CARVYKTI data require clinical and commercial interpretation
Legend reported that 10 of 20 CARTITUDE-2 Cohort A patients remained alive and progression-free without maintenance therapy five years after one infusion. The result supports durability, but the small cohort limits extrapolation to broader uptake. Market digestion of the September 25 presentation remains the near-term event. [#IR-2026-09-25] Company release
Prob 85.00% • Move 6.00% • Priced-in 60.00%

Short-term Catalysts

Next few weeks

CARVYKTI growth must translate into sustained operating profit
2026-12-25
Second-quarter CARVYKTI net trade sales rose 50% year over year to approximately $657 million; Legend reported $57.7 million of operating income and $63.1 million of adjusted net income. Future results must show whether growth and operating leverage persist as commercial spending and pipeline investment continue. No next-results date was confirmed. [#IR-2026-08-11] Company earnings release
Prob 65% • Move 10% • Priced-in 50%

Long-term Catalysts

Months to a year

LB2501 follow-up must validate early in vivo CAR-T responses
2027-09-26
Legend reported six responses among six higher-dose Phase 1 LB2501 patients, including five complete responses, without lymphodepletion. The sample and follow-up are too limited to assign substantial platform value; durability and safety in additional patients are the relevant milestones. No readout date was confirmed. [#IR-2026-06-14] Company release
Prob 50% • Move 15% • Priced-in 30%

Risks

CARTITUDE-2 Cohort A's five-year result covers only 20 patients; broader clinical and commercial implications remain uncertain.
CARVYKTI concentration makes sales growth, access, manufacturing execution and safety disproportionately important.
LB2501 efficacy and safety observations are preliminary Phase 1 findings from a small cohort.
Legend's June 2026 offering strengthened cash but illustrates potential dilution and the funding needs of pipeline development. [#IR-2026-08-11]

Peers

Symbol	Summary
AMGN	Amgen is a broad biotechnology risk benchmark, not a direct CARVYKTI operating peer; its scale and diversification limit valuation comparability.
GILD	Gilead provides an adjacent commercial cell-therapy benchmark through Kite, but its diversified portfolio makes a direct Legend valuation multiple unreliable.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-09-26

Loading AI feed…

Symbol

Summary

AMGN

Amgen is a broad biotechnology risk benchmark, not a direct CARVYKTI operating peer; its scale and diversification limit valuation comparability.

GILD

Gilead provides an adjacent commercial cell-therapy benchmark through Kite, but its diversified portfolio makes a direct Legend valuation multiple unreliable.